The UK and US have announced a major commercial pact that will maintain no duties on UK pharmaceutical products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to boost spending on medicines through the NHS. This move guarantees that duties on these vital exports will stay at zero for a period of 36 months.
This development follows recent threats to hike import taxes on branded drug products, with increases discussed reaching 100%.
"This agreement with the United Kingdom strengthens the international landscape for new treatments and introduces long-overdue fairness to U.S.–U.K. drug exports," a release declared.
Trade Importance
Drugs constitute one of the UK's biggest exports to the US, which is easily the largest market for large companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period prior to the third quarter, the UK exported pharmaceutical products valued at billions to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This deal protects employment, increases funding and paves the way for the UK to establish itself as a international leader for life sciences," a government official commented.
Key UK Commitments
The pact includes several notable commitments from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise overall NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The percentage pharmaceutical firms must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
This agreement follows a protracted dispute between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were exacerbated by arguments that US customers were charged a premium for the same drugs than patients in the other developed nations.
Recently, several large manufacturing plans in the UK have been paused or abandoned, while substantial investments have been pledged toward American operations.
A senior figure acknowledged that the NHS must spend more on treatments, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
